Correlations between immune and metabolic serum markers and schizophrenia/bipolar disorder polygenic risk score in first‐episode psychosis

2019 ◽  
Vol 14 (4) ◽  
pp. 507-511 ◽  
Author(s):  
Carlo Maj ◽  
Sarah Tosato ◽  
Roberta Zanardini ◽  
Antonio Lasalvia ◽  
Angela Favaro ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Risk Score ◽  
First Episode Psychosis ◽  
Serum Markers ◽  
First Episode ◽  
Polygenic Risk Score ◽  
Polygenic Risk ◽  
Episode Psychosis

scholarly journals Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis

2019 ◽  
Vol 176 (1) ◽  
pp. 21-28 ◽  
Author(s):  
Jian-Ping Zhang ◽  
Delbert Robinson ◽  
Jin Yu ◽  
Juan Gallego ◽  
W. Wolfgang Fleischhacker ◽  
...  
Keyword(s):  
Risk Score ◽  
First Episode Psychosis ◽  
First Episode ◽  
Polygenic Risk Score ◽  
Polygenic Risk ◽  
Antipsychotic Efficacy ◽  
Episode Psychosis

scholarly journals The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Diego Quattrone ◽  
Ulrich Reininghaus ◽  
Alex L. Richards ◽  
Giada Tripoli ◽  
Laura Ferraro ◽  
...  
Keyword(s):  
Risk Score ◽  
First Episode Psychosis ◽  
Cannabis Use ◽  
Psychotic Symptoms ◽  
First Episode ◽  
Polygenic Risk Score ◽  
Symptom Dimensions ◽  
Polygenic Risk ◽  
Episode Psychosis ◽  
The Eu

AbstractDiagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms and experiences using item response bi-factor modelling. Linear regression was used to test the associations between these dimensions and SZ-PRS, as well as the combined effect of SZ-PRS and cannabis use on the dimensions of positive psychotic symptoms and experiences. We found associations between SZ-PRS and (1) both negative (B = 0.18; 95%CI 0.03–0.33) and positive (B = 0.19; 95%CI 0.03–0.35) symptom dimensions in 617 FEP patients, regardless of their categorical diagnosis; and (2) all the psychotic experience dimensions in 979 controls. We did not observe associations between SZ-PRS and the general and affective dimensions in FEP. Daily and current cannabis use were associated with the positive dimensions in FEP (B = 0.31; 95%CI 0.11–0.52) and in controls (B = 0.26; 95%CI 0.06–0.46), over and above SZ-PRS. We provide evidence that genetic liability to schizophrenia and cannabis use map onto transdiagnostic symptom dimensions, supporting the validity and utility of the dimensional representation of psychosis. In our sample, genetic liability to schizophrenia correlated with more severe psychosis presentation, and cannabis use conferred risk to positive symptomatology beyond the genetic risk. Our findings support the hypothesis that psychotic experiences in the general population have similar genetic substrates as clinical disorders.

scholarly journals Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis

2017 ◽  
Vol 184 ◽  
pp. 116-121 ◽  
Author(s):  
Sarojini M. Sengupta ◽  
Kathleen MacDonald ◽  
Ferid Fathalli ◽  
Anita Yim ◽  
Martin Lepage ◽  
...  
Keyword(s):  
Risk Score ◽  
First Episode Psychosis ◽  
First Episode ◽  
Polygenic Risk Score ◽  
Specific Symptom ◽  
Symptom Dimensions ◽  
Polygenic Risk ◽  
Episode Psychosis

scholarly journals S125. THE ROLE OF DUP, DUI AND POLYGENIC SCORE FOR SCHIZOPHRENIA ON COGNITION IN ATHENS FEP STUDY SAMPLE

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S82-S83
Author(s):  
Stefanos Dimitrakopoulos ◽  
Alex Hatzimanolis ◽  
Pentagiotissa Stefanatou ◽  
Lida-Alkisti Xenaki ◽  
Nikos Stefanis
Keyword(s):  
Risk Score ◽  
Cognitive Deficit ◽  
Assessment Tool ◽  
First Episode Psychosis ◽  
First Episode ◽  
P Value ◽  
Polygenic Risk Score ◽  
Inform Consent ◽  
Polygenic Risk ◽  
Episode Psychosis

Abstract Background It remains unclear which biological mechanisms affect neurocognition in first episode psychosis (FEP) patients. There is minimal evidence from current literature suggesting an association between duration of untreated psychosis (DUP) or duration of untreated illness (DUI) and cognitive decline in FEP patients. It is still controversial whether genetic factors, such as polygenic risk score for schizophrenia, determine observed cognitive deficits. The study of interplay between DUP, DUI and genetic risk factors might be important to understand underlying pathways. Methods Ninety FEP patients where recruited during Athens First-Episode Psychosis Research study between 2015–2018. All participants provided inform consent. DUP for each patient was defined by NOS-DUP (Nottingham onset schedule: modified DUP version) assessment tool and DUI was determined using the symptom onset in schizophrenia (SOS) inventory. DNA was collected in order to create polygenic risk score (PGC) for schizophrenia for each individual using SNPs selected according to the significance of their association with the phenotype at nominal p-value thresholds of 0,05. WAIS-IV total score and subscales, i.e. Verbal Comprehension (VC), Perceptual Reasoning (PR), Working Memory (WM), Processing Speed (PS) and moreover index differences between these 4 subscales were applied as a measure of cognitive deficit. Results Generalized linear model analysis, after adjustment for years of education and gender, found no significant main effect of DUP, DUI or PGC on any cognitive subscale. Furthermore, conducting an exploratory analysis for possible interactions between DUP/DUI and PGC (n=90), we found statistically significant findings of DUP x PGC (F=8,175, p=,005) and DUI x PGC (F=5,592, p=,021) for the cognitive variable of VC/WM difference. The interplay between DUP and PCG and DUI and PGC was associated with observed differences between VM and WM in our FEP sample. Discussion Our preliminary results are consistent with recent literature suggesting that neurocognition is not determined by DUP, DUI or PGC for schizophrenia. Novel approach based on WAIS-IV indexes of interest allows to explore subtle differences between cognitive subdomains. Elucidating underlying interplay between genetic and disease-related mechanisms could be important to understand the core feature of cognitive deficit in FEP patients.

scholarly journals Schizophrenia polygenic risk score and cannabis use modify psychosis expression in first episode psychosis patients and population controls

2019 ◽  
Author(s):  
Diego Quattrone ◽  
Ulrich Reininghaus ◽  
Alex L. Richards ◽  
Giada Tripoli ◽  
Laura Ferraro ◽  
...  
Keyword(s):  
Continuous Distribution ◽  
First Episode Psychosis ◽  
Cannabis Use ◽  
Psychotic Symptoms ◽  
First Episode ◽  
Polygenic Risk Score ◽  
Small Magnitude ◽  
Polygenic Risk ◽  
Episode Psychosis ◽  
Population Controls

AbstractBackgroundDiagnostic categories within the psychosis spectrum are widely used in clinical practice, however psychosis may occur on a continuum. Therefore, we explored whether the continuous distribution of psychotic symptoms across categories is a function of genetic as well as environmental risk factors, such as polygenic risk scores (PRSs) and cannabis use.MethodsAs part of the EU-GEI study, we genotyped first episode psychosis patients (FEP) and population controls, for whom transdiagnostic dimensions of psychotic symptoms or experiences were generated using item response bi-factor modelling. Linear regression was used, separately in patients and controls, to test the associations between these dimensions and schizophrenia (SZ) PRSs, as well as the combined effect of SZ-PRS and cannabis use on the positive symptom/experience dimensions.ResultsSZ-PRS was associated with negative (B=0.18; 95%CI 0.03 to 0.34) and positive (B=0.19; 95%CI 0.03 to 0.36) symptom dimensions in 617 FEP, and with all the psychotic experience dimensions in 979 controls. The putative effect of SZ-PRS on either symptom or experience dimensions was of a small magnitude. Cannabis use was additionally associated with the positive dimensions both in FEP (B=0.31; 95%CI 0.11 to 0.52) and in controls (B=0.26; 95%CI 0.06 to 0.46), independently from SZ-PRS.ConclusionsWe report two validators to the latent dimensional structure of psychosis. SZ risk variants and cannabis use independently map onto specific dimensions, contributing to variation across the psychosis continuum. Findings support the hypothesis that psychotic experiences have similar biological substrates as clinical disorders.

Distinct Genetic Profiles in Postpartum Depression With Different Trajectory of Illness

2020 ◽  
Author(s):  
Nagahide Takahashi ◽  
Hanae Tainaka ◽  
Tomoko Nishimura ◽  
Taeko Harada ◽  
Akemi Okumura ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Postpartum Depression ◽  
Risk Score ◽  
Association Studies ◽  
Depression Scale ◽  
Polygenic Risk Score ◽  
Genome Wide Association Studies ◽  
Gene Set Enrichment ◽  
Polygenic Risk ◽  
Gene Set

Abstract BackgroundPostpartum depression (PPD) is a common and highly heritabledisorder in the postnatal period of new mothers. The development of PPD is shown to affectneurodevelopment in children and recent evidence suggests thatthe trajectory of PPDisalso associated with children’s neurodevelopment and mental conditions. Thus, early identification and intervention for individuals at high risk of PPD are urgently needed.Additionally, it is not clear whether genetic factors affect thetrajectory of PPD. Therefore, using a polygenic risk score (PRS) approach, we investigated if PRS for depression (Depression-PRS) and bipolar disorder (Bipolar-PRS) are associated with the development and clinical course of PPD.Methods Usingrecent large genome-wide association studies(GWAS) of depression and bipolar disorder as discovery cohorts, we calculatedDepression-PRS and Bipolar-PRS in each individual. Then, we investigated the possible association between Depression-PRS and Bipolar-PRS with the development andtrajectory of PPD insubjects from the Hamamatsu Birth Cohort for mothers and children (n = 136). Depressive symptoms were assessed using the Edinburgh Postpartum Depression Scale. Gene-set enrichment analyses were used to identify pathways underlying these conditions. ResultsDepression-PRS was significantly higher in subjects with PPD than in those without PPD(t = -3.283, P = 0.002)and logistic analysis showed that Depression-PRS significantly increases therisk of developing PPD(OR [SE] = 2.274 [0.585], P = 0.002). Furthermore, Depression-PRS was positively associated with continuity of PPD (β [SE]=1.621 [0.672]; P = 0.032).Gene-set enrichment analyses revealed that pathways such as“response to hormone”(β[SE] -2.285[1.002], P < 0.001) and “epigenetic regulation”(β[SE] 2.831 [1.317], P < 0.001) were involved in the continuity of PPD. ConclusionThese preliminary findings indicate that the genetic component plays an important role not only in the development but also inthe continuity of PPD. A polygenic risk score approach could be useful to identify subjects at risk for PPD, especially for persistent PPD,who needcareful monitoring and intervention after delivery.

scholarly journals Letter to the editor: Is polygenic risk for Parkinson's disease associated with less risk of first episode psychosis?

2019 ◽  
Vol 50 (1) ◽  
pp. 173-176
Author(s):  
Diego Quattrone ◽  
Alex Richards ◽  
Ulrich Reininghaus ◽  
Evangelos Vassos ◽  
Michael O'Donovan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
First Episode Psychosis ◽  
First Episode ◽  
Polygenic Risk ◽  
Letter To The Editor ◽  
Episode Psychosis

POLYGENIC RISK SCORE ANALYSES OF SYMPTOMS AND TREATMENT RESPONSE IN A FIRST EPISODE SCHIZOPHRENIA COHORT

2019 ◽  
Vol 29 ◽  
pp. S869
Author(s):  
Marcos Santoro ◽  
Vanessa Ota ◽  
Simone de Jong ◽  
Cristiano Noto ◽  
Fernanda Talarico ◽  
...  
Keyword(s):  
Treatment Response ◽  
Risk Score ◽  
First Episode ◽  
Polygenic Risk Score ◽  
Polygenic Risk ◽  
First Episode Schizophrenia
Sign in / Sign up

Export Citation Format

Share Document